| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.33 | 6e-13 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.26 | 1e-08 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | 0.2 | 1e-08 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.18 | 4e-08 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.18 | 6e-08 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-07 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.17 | 7e-07 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-06 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |